NCT04087200Recruiting
Protective Effect of Early High Dose stATins On Cardiovascular and Renal Events in Acute Coronary Syndrome
The Protective Effect of Early High Dose High-intensity Statins on Cardiovascular and Renal Events in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 12 Sept 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Registration of all ACS patients (STEMI and NSTEMI) admitted to the cardiology ward and scheduled for early invasive strategy. The aim is to evaluate the protective effects of early (on admission) high-dose high-potency statin therapy on early and mid-term cardiac and renal events in this subset of patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2500 (estimated)
- First submitted
- 30 Aug 2019
- Start date
- 1 Dec 2016
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Centro Cardiopatici Toscani
- Diseases
- Coronary artery disease
- NCT number
- NCT04087200
What you commit to
- Study type: Observational
- Planned participants: 2500
- From 1 Dec 2016 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- contraindication to statin therapy
Other
- refusal of consent
Who the study is looking for
- Acute coronary syndrome (ST elevation and non ST elevation)
- Early invasive strategy
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cardiology Division, Prato Hospital Coordinator of this site? Confirm its status | Prato | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.